Study of BHV-1400 in IgA Nephropathy

Biohaven

Status and phase: Enrolling; Phase 1

Conditions: IgA Nephropathy

Treatments: Drug: BHV-1400

Study type: Interventional

Funder types: Industry

Identifiers

NCT07054684

BHV1400-102

Details and patient eligibility

About

The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).

Enrollment: 10 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

1. Participants must have biopsy-confirmed IgA Nephropathy

Key Exclusion Criteria:

1. Any secondary IgAN
2. Any cause of chronic kidney disease not diagnosed as IgAN or due to non-IgAN cause

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

BHV-1400

Experimental group

Treatment:

Drug: BHV-1400